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HEPARIN-ANTIVENOM ASSOCIATION: DIFFERENTIAL NEUTRALIZATION EFFECTIVENESS IN
Bothrops atrox AND Bothrops erythromelas ENVENOMING
Antônio Luiz R. BOECHAT(1), Cristiano S. PAIVA(1), Francisco Oscar FRANÇA(2) & Maria Cristina DOS-SANTOS(3)
SUMMARY
Heparin, in some regions of Brazil has been used in the treatment of bothropic accidents, but the data found in the literature are
inconclusive about its effectiveness. The venoms of Bothrops atrox and of B. erythromelas were characterized according to their
biological activities. The capacity of heparin in neutralizing these activities was tested with doses of 3 and 6 IU in isolated form and
associated to Antibothropic Serum (ABS). It was verified that heparin, in doses of 3 and 6 IU, was not effective in neutralizing the
desfibrinating and edema-forming activities of B. atrox venom and the hemorrhagic and coagulant actions of both venoms. Heparin
diminished the effectiveness of the ABS in the neutralization of the hemorrhagic and edema-forming activities of the B. atrox venom.
However, heparin in the 6 IU dose was capable of neutralize the edema-forming of the B. erythromelas and increase the effectiveness
of the ABS. Heparin also neutralized the phospholipasic A2 activity of B. atrox (14.3%) and B. erythromelas (28.0%) venoms. For B.
erythromelas venom, the associated treatment, heparin and ABS, was more effective in the neutralization of its lethal activity.
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INTRODUCTION
ln Brazil,
 
snake venoms accidents represent an important public health
problem. Around 90% of which are caused by snakes of the Bothrops
genus. The species Bothrops jararaca (South and Southeast), Bothrops
moojeni (Center-West), Bothrops erythromelas (Northeast) and Bothrops
atrox (North) which are responsible for most of these accidents, with
humans, are distributed in different regions of Brazil5.
Despite the interspecies and intra-species variations existent in the
chemical composition of venom, generally, the signs and symptoms
presented by patients that have had accidents with Bothrops genus are:
(a) local - pain, edema, equimosis, hemorrhage, myonecrosis; (b)
systemics - blood incoagulability, hemorrhages being it possible to also
occur shock and acute kidney failure. In severe cases of envenoming,
these local effects may lead to permanent tissue loss, disability or
amputation18,25.
The effective therapeutic treatment for ophidian accidents is sero-
therapy. Antivenom serotherapy, however, although efficient for
neutralization of systemic manifestations of bothropic venom, contribute
little to the improvement of the local tissue damage6. Experiments on
mice, show that antivenoms are effective in neutralizing necrosis and
local hemorrhage, only when injected at the same time or immediately
after poison inoculation15,26. Therefore, new therapies parallel antivenom
injection, would be fundamental in minimizing local effects induced by
snakes venoms, specially from Bothrops genus.
The use of heparin as a treatment in snake venom accidents, was
first proposed in the late 40’s by AHUJA et al.2 and AHUJA & SINGH1.
Heparin is a family of glycosaminoglycans, highly sulfated, with
molecular weight that varies between 5,000 and 40,000, capable of
interacting with the antithrombin III, producing anticoagulant effect.
The clinical use of heparin has been secured as anticoagulant and
antithrombotic, but, recently, a possible anti-inflammatory action has
been suggested21.
Due to its strongly polyanionic nature, heparin can interact with
many molecules that have cationic sites33. Among the substances capable
of interacting with heparin, are included proteins from the extracellular
matrix (fibronectin, laminae, vitronectin), proteins involved in lipid
metabolism, components of the complement system, serine protease
inhibitors, viral proteins, and enzymes21,22,33. Within the enzymes, heparin
can interact with phospholipase A2, present in many snake venoms,
affecting8,9,12, or not7,19 the enzymatic activity of these proteins.
TINOCO30 in a clinical and experimental study with dogs, suggested
the use of heparin in substitution of specific serum therapy in the case of
poisoning by Bothrops jararaca.
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In 1975, NAHAS et al.27 demonstrated that heparin was not capable
of neutralizing the thrombin-like activity of bothropic venoms and in
prevention of the desfibrinating syndrome, induced by Bothrops jararaca
venom. Nevertheless, they observed that heparin was capable of
neutralizing the venom that acts only on factor X. Those venoms that act
directly on the fibrinogen and on factor X, did not have their coagulant
activity blocked by heparin.
Heparin neutralized the myotoxic activity of bothropstoxin enzyme
of Bothrops jararacussu venom. This protein belongs to phospholipase
A2 group that do not have neurotoxic activity23,24. Heparin inhibited in
vitro the citotoxic activity of Bothrops asper venom and also neutralized
in vivo22 its myotoxic activity.
The present experiments were undertaken to verify the action of
commercial heparin (Liquemine-Roche) within the main biological
activities (hemorrhagic, in vitro and in vivo coagulant, edematogenic,
phospholipasic and lethality) of the Bothrops atrox and Bothrops
erythromelas venoms, that are responsible for most accidents in the North
and Northeast of Brazil, respectively.
MATERIAL AND METHODS
Venoms: Lyophilized venom of Bothrops atrox was obtained at the
Centro de Animais Peçonhentos do Instituto de Medicina Tropical do
Amazonas, Manaus (AM), Brazil. The freezing dried venom of Bothrops
erythromelas was kindly given by Prof. Dr. Augusto S. Abe of the
Departamento de Zoologia, Universidade Estadual de São Paulo, Rio
Claro (SP), Brazil. The venoms were kept at -20 °C and diluted at the
moment of the use.
Animals: Outbred Swiss mice (18 - 22 g), females proceeding from
the Instituto Nacional de Pesquisas da Amazônia (INPA - Manaus,
Amazonas, Brazil) were used in the experiments. The animals were kept
in plastic cages receiving water and food ad libitum under controlled
temperature conditions.
Bovine Fibrinogen: Samples of lyophilized bovine fibrinogen were
donated by the Seção de Hematologia do Instituto Butantan (São Paulo,
SP, Brazil).
Heparin (HEP): Heparin used in the experiments was purchased
from Roche (Liquemine®).
Antibothropic Serum (ABS): The antibothropic serum used in the
neutralization experiments was produced by Instituto Butantan (São
Paulo, SP, Brazil) -Lot 9406081.
Biological activities of venoms
Lethal Dose 50% (LD5O): For determination of the LD50, different
doses of venoms were injected by intraperitonial route (i.p). Four mice
were used for each venom dose. Deaths were recorded after 24 and 48
hours. The LD50 were calculated by the probit analysis11.
Minimum Hemorrhagic Dose (MHD): Hemorrhage was quantified
by the method of GUTIÉRREZ et al.16. Four mice were used for each
venom dose. The venom doses were injected by intradermic route. Mice
were killed by ether inhalation 2 hr after injection, and the areas of
hemorrhage measured on the internal surface of the dissected skin. The
minimum hemorrhagic dose was defined as the amount of venom which
induced a hemorrhagic area of 10 mm diameter.
Minimum Coagulant Dose: The plasma and fibrinogen minimum
coagulant doses were estimated as previously described29. The minimum
coagulant dose of a venom is defined as the minimum amount of venom
resulting in clot formation within 60 sec at 37 °C. The tests were done in
triplicate.
Minimum Defibrinagenating Dose (MDD): For defibrinating
activity the method described by GENÉ et al.13 was used. Briefly, five
doses for each venom were used and, for each dose, four mice. The
venom doses were inoculated by intravenous route. One hour after the
injection of the venom, blood samples (0.1 ml) were collected from the
animals. Blood was placed in tubes and kept at 37 °C until clotting
occurred.
Minimum Edema-forming Dose (MED): The minimum edema-
forming doses were determined according to the procedures of
YAMAKAWA et al.32 with some modifications. Briefly, hind paw edema
was produced by a subplantar injection of 50l venom solution or an
equal volume of saline into the right and left hind-paw of mice,
respectively. The paws (right and left) were measured with a calliper
(Mitutoyo) at 0, 30, 60, 120, 180, 240, 300, 360 minutes. The minimum
edema-forming dose was defined as the amount of venom that induced
an edema of 30%.
Determination of the Heparin Doses: The heparin doses were
obtained with basis on that used in human therapeutics (60 kg of body
mass) and calculated for mice with 20 grams of body mass.
Anticoagulant Effect of the Heparin: The doses of heparin obtained
by the previous method were injected in mice, by intravenous route and
the effect of each dose on the blood coagulation was observed. For each
dose, four mice were used.
Effects of Heparin on the biological activities of Venoms
Group Schemes for the neutralization experiments: For all the
neutralization experiments (hemorrhagic, edematogenic, desfribrinating
and lethality activities) six groups of four animals each were used, for
each venom, and received the following treatment: group I (GI) - venom
in the corresponding doses for each activity (venom control); Group II
(GII) - venom and heparin in a 3 IU dose; Group III (GIII) - venom and
heparin in a 6 IU dose; Group IV (GIV) - venom and Antibothropic
Serum (ABS); Group V (GV) - venom, ABS and 3 IU heparin; Group
VI (GVI) - venom, ABS and 6 IU heparin. The doses of heparin were
injected by intravenous route (e.v). A 100µl ABS dose was used for each
animal and injected (e.v) in all experiments. Heparin and ABS were
injected immediately after injection of the venom (zero time).
• Hemorrhagic: The challenge dose used, for each venom, in the
neutralization of the hemorrhagic activity corresponded to three times
the Minimum Hemorrhagic Dose and was injected by intradermic
route at zero time. The animals were sacrificed two hours later, with
ethylic ether and the hemorrhagic halos were measured.
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• Edematogenic: The challenge dose was equivalent to three times
the Minimum Edematogenic Dose of the corresponding venom and
was injected in the right paw. Saline, used as control, was injected in
the left paw, as described previously. The paws were measured at
times 0, 30, 60, 120, 180, 240, 300 and 360 minutes after injection
of the venom and saline.
• Desfibrinating: The dose used, for each venom, corresponded to
three times the Minimum Desfibrinating Dose and was injected by
i.v. route, at zero time. Blood samples were collected one hour after
the injection, kept at 37 °C and the time of coagulation, for each
blood sample, was observed for one hour.
• Lethality: A 250 µg challenge dose was used for each venom injected
by i.v. route, at zero time. The time of death and the reactions
presented by the animals were observed and noted. The animals were
submitted to necropsy and the organs (liver, lungs, kidneys, brain
and heart) kept in a 10% formaldehyde solution. Histopathological
analysis was performed by classical techniques.
• Coagulant Activity:
• On the fibrinogen. The dose of venom used was equivalent to
two times the minimum coagulant dose on the fibrinogen (MCD-
F). The venom (2 MCD-F) was incubated at 37 °C, along with
the different doses of heparin (3, 6, 12, 24, 48 IU) for 30 minutes.
After incubation, 100µl of each venom solution and HEP were
added to 400µl of Bovine fibrinogen (2g/L) and the time of
coagulation was observed.
• On the plasma. The dose of venom used was equivalent to two
times the minimum coagulant dose on human plasma, used as
substrate, following the methodology mentioned above.
• Phospholipase A2 Activity (Indirect Hemolytic Assay): The method
described by GUTIÉRREZ et al.17 was used to evaluate this activity.
100µl samples of venom solution (10mg/ml) were incubated with 100µl
of heparin, ABS and saline, at 37 °C, for 30 minutes. After incubation,
10µl of each mixture was added to wells, previously covered with
agarose containing sheep erythrocytes and egg yolk. The hemolysis
halos were measured 24 hours after sample application.
• Statistical Analysis. The T Student test was applied, using the
Statgraphics Plus statistical program to verify the statistical difference
between groups. The value of p=0.05 was defined.
RESULTS AND DISCUSSION
Characterization of Biological Activities of the Venoms: The values
obtained for the minimum doses of venoms activities are showed in
Table 1. These values were similar to the ones described by other
authors3,10,28. The venom of the Bothrops erythromelas has no coagulant
activity on bovine fibrinogen. This venom, however, was more toxic,
for the lethal and coagulant activities on the plasma, than the venom of
the B. atrox and less active, for the edematogenic, hemorrhagic and
desfibrinating actions. Although FERREIRA et al.10 showed that
hemorrhagic and edematogenic actions are related to the lethality of
bothropic venom, this fact was not observed in this experiments.
Determination of Experimental Doses of Heparin: The doses of
heparin used on mice corresponding to the ones injected, in human
therapeutics, for individuals weighing 60kg. From the blood samples
collected from the animals that received different doses of heparin (3, 6,
12, 24 and 48 IU) it was observed that the blood coagulation time
remained normal (<5 minutes) for the animals that received 3 and 6 IU
heparin doses. The time of blood coagulation was altered, occurring the
formation of microclots and coagulation after 30 minutes, for the animals
that received the 12 UI dose; and uncoagulative (> 60 minutes) for the
animals that received the 24 and 48 IU doses. Based on these results, 3
and 6 IU heparin doses were chosen for the neutralization tests, since
the higher doses would induce alterations in the blood coagulation.
Study of Neutralizing Effect of Heparin on the Coagulant Activity:
Heparin was capable of neutralizing the thrombin time coagulant activity
of the B. atrox (Table 2) only in the doses over 12 IU (equal to 36,000
IU in human therapeutics).
Heparin did not present, in the tested doses, inhibitory effect of the
coagulant action of B. atrox venom on the human plasma (Table 2).
However, in the 12, 24 and 48 IU doses, heparin was capable of partially
neutralize the coagulant action of B. erythromelas venom on the plasma
(Table 2).
NAHAS et al.27 demonstrated that heparin neutralizes only the
coagulant activity of venoms that act selectively on the factor X of the
blood coagulation system. This is the reason that heparin did not inhibit
the coagulant activity of B. atrox venom, since this venom acts on factor
X, on the prothrombin, and on the flbrinogen (thrombin-like action).
The B. erythromelas venom which acts on the factor X and does not
have thrombin-like activity, explains the partial neutralization by heparin
of the coagulant activity on the human plasma.
Neutralizing Effect of Heparin on the Desfibrinating Activity: The
Table 1
Establishment of the minimum doses for the venom of Bothrops atrox and
Bothrops erythromelas
Biological Activities Bothrops Bothrops
 atrox erythromelas
Lethality (LD50) 5.6 mg/kg 3.0 mg/kg
(4.4 – 6.6 mg/kg) (2.5 – 3.5 mg/kg)
Coagulant on Fibrinogen 77.5 mg/l *
(MCD-F)
Coagulant on Plasma (MCD-P) 150.0 mg/l 52.5 mg/l
Edematogenic (MED) 1.2 g/animal 1.4 g/animal
Hemorrhagic (MHD) 2.9 g/animal 5.9 g/animal
Desfibrinating (MDD) 10.0 g/animal 45.0 g/animal
* B. erythromelas venom did not present coagulant activity on the bovine
fibrinogen.
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results presented in Table 3 demonstrate that heparin was not capable of
neutralizing the desfibrinating action (MDD), in vivo, of the B. atrox
venom in the doses tested. On the other hand, the antibothropic serum
(ABS) was capable of totally neutralizing this activity, and its action
was not affected when associated with heparin (Table 3).
Due to the proximity of the Lethal Dose 50% and the Minimum
Desfibrinating Dose (MDD) of B. erythromelas venom (see Table 1), it
was not possible to study the neutralizing effect of the heparin, since the
animals died before one hour after the injection of three times the MDD.
Neutralizing Effect of Heparin on the Hemorrhagic Activity:
Heparin did not neutralize the hemorrhagic activity of B. atrox venom
as shown in Table 4. There was a significant dose-dependent increase of
the hemorrhagic halo produced by the venom, compared to the control,
when the animals received heparin (3 and 6 IU doses) at the same time
(Table 4).
The antibothropic serum (ABS) was capable of neutralizing 38% of
the hemorrhagic activity of B. atrox venom. The antivenom’s action was
totally neutralized when the animals were treated with ABS and heparin
in the 3 and 6 IU doses, being observed, in these groups, significant
increases of the hemorrhage compared to the group that received
antibothropic serum, alone. MELO et al.24 reported that polyanions with
high molecular weight, as heparin family, are not effective in neutralizing
the hemorrhagic activity of B. jararacussu venom. LOMONTE et al.22
demonstrated through histological sections that hemorrhagic activity of
B. asper venom was potencialized by addition of heparin standard
solution, which has high molecular weight polyanions capable of
interacting with the antithrombin III, promoting the anticoagulant effect.
In addition, when low weight heparin was used, the increase in the
hemorrhagic activity was not observed22.
There was no significant difference between the hemorrhage
produced by B. erythromelas venom in the control and experimental
groups that received heparin (3 and 6 IU doses). The bothropic antivenom,
on the other hand, was capable of neutralizing 57% of the hemorrhagic
activity, without having its action harmed by the heparin in the studied
doses - 3 and 6 IU.
Neutralizing Eftect of Heparin on the Edematogenic Activity:
Figure 1 shows the action of heparin, in the 3 and 6 IU doses, on the
kinetics of edema formation produced by the venom of B. atrox in the
dose corresponding to three times the Minimum Edema-forming Dose
(MED). It was observed that the antibothropic serum reduced, in a
significant way, the edema from 180 minutes on, obtaining its maximum
effect of neutralization (44.6%), in 360 minutes. GUTIÉRREZ &
LOMONTE18 demonstrated that the antivenoms are not capable of totally
neutralizing the edematogenic activity. Heparin, by itself, did not induce
a significant reaction in the edema levels. Interestingly, the presence of
heparin decreased the anti-edematogenic activity of the antiserum. The
results presented for the edematogenic action of B. atrox venom show
that heparin was not effective in neutralizing this activity.
Effects of heparin, in the 3 and 6 IU doses, on the edematogenic activity
of B. erythromelas venom are expressed in Figure 2. It was observed that
the bothropic antivenom promoted an 85.8% reduction of the edema
Table 4
Neutralization of the hemorrhagic activity of the venom of the Bothrops atrox and Bothrops erythromelas
Groups Hemorrhagic area (mm2) Protection Hemorrhagic area (mm2) Protection
Bothrops atrox (%) Bothrops erythromelas (%)
Control (venom) 128.2±14.5 - 310.3±41.2 -
Heparin 3UI 169.2±14.1 - 399.2±56.5 -
Heparin 6 UI 207.3±22.3 - 401.3±109.9 -
Antibothropic 78.6±22.2 38.7 130.3±37.2 57.9
Antibothropic + heparin 3 UI 132.3±18.9 - 159.6±14.1 48.5
Antibothropic + heparin 6 UI 138.0±6.1 - 157.3±30.7 49.3
Table 2
Neutralization of the coagulant activity of the venoms
Heparin Bovine Fibrinogen Human Plasma
(IU)  (min.) (sec.)
B. atrox B. erythromelas B. atrox B. erythromelas
- <2 * 51 62.5
3 <2 * 48 62
6 <2 * 54 63
12 >60 * 55 91
24 >60 * 63 127
48 >60 * 44 146
* B. erythromelas venom did not present coagulant activity on the bovine
fibrinogen.
Table 3
Neutralization of the desfibrinating activity of Bothrops atrox
venom by heparin
Heparin (IU) Venom  Antibothropic Time of Coagulation
(min)
- + - > 60
3 + - > 60
6 + - >60
- + + < 10
3 + + < 10
6 + + < 10
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Fig. 1 - The effect of heparin (3 and 6 IU) in neutralizing the edematogenic activity of Bothrops atrox venom: Group I - the mice were injected with a dose of 3.6 g/animal (3DME) of the
Bothrops atrox venom; Group II - received the Bothrops atrox venom in a dose of 3.6 g/animal and 3 IU of heparin; Group III - venom in a dose of 3.6 g/animal and 6 IU of heparin; Group
IV - venom in a dose of 3.6 g/animal and Antibothropic serum; Group V - venom in a dose of 3.6 g/animal, Antibothropic serum and 3 IU of heparin; Group VI - venom in a dose of
3.6 g/animal, Antibothropic serum and 6 IU of heparin.
Fig. 2 - The effect of heparin (3 and 6 IU) in neutralizing the edematogenic activity of Bothrops erythromelas venom: Group I - the mice were injected with a dose of 4.2 g/animal (3DME) of
Bothrops erythromelas venom; Group II - received Bothrops erythromelas venom in a dose of 4.2 g/animal and 3 IU of heparin; Group III - venom in a dose of 4.2 g/animal and 6 IU of
heparin; Group IV - venom in a dose of 4.2 g/animal and Antibothropic serum; Group V - venom in a dose of 4.2 g/animal, Antibothropic serum and 3 IU of heparin; Group VI - venom in
a dose of 4.2 g/animal, Antibothropic serum and 6 IU of Heparin.
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produced by this venom, in the sixth hour after injection. Heparin caused
a significant anti-edematogenic effect only in the 6 IU dose. It is interesting
to note that, up to 180 minutes, the effect of the heparin does not
significantly differ from the neutralizing effect produced by the
antibothropic, having it promoted maximum neutralizing effect (52.9%)
in 360 minutes. When associated to the antibothropic venom, heparin
induced according to the dose the following results: (a) with 3 IU dose,
the neutralization did not differ from that produced by the antivenom,
alone; (b) with 6 IU dose, the action of the antibothropic improved, at the
sixth hour (360 minutes), reducing the edema formation to 94.1%.
The neutralization of local action of B. atrox venom by the
antibothropic and by the heparin was less effective than B. erythromelas
venom (Figures 1 and 2). This phenomenon can be explained considering
the difference of the phospholipasic and proteolytic activities of both
venoms. The indirect hemolytic activity (by phospholipase A2) of the
venom is presented in Table 5, showing that the venom of B. erythromelas
has a higher phospholipasic A2 activity. B. atrox venom is known as one
of the most proteolytic bothropic venoms3,10,28. Furthermore, it is more
hemorrhagic than B. erythromelas venom. Therefore, it is possible to
suggest that the edematogenic activity of B. atrox venom may be related
with the proteolytic and hemorrhagic activities. On the other hand, the
edematogenic activity of B. erythromelas venom may be due to a potent
phospholipasic activity. The observation of necrosis, flictens and
hemorrhage on the paws of the animals that received the venom of the
Bothrops atrox corroborates this hypothesis. Animals that received
Bothrops erythromelas venom, besides edema, presented only a discreet
local hemorrhagic action, without signs of macroscopic tissue destruction.
According to this hypothesis, the intense tissue destruction produced by
the Bothrops atrox venom (microvasculature, conjunctive tissue), along
with the overcoming of the microtrombs18 hinders the access of antibodies
and heparin to the site of venom inoculation.
Finally, it remains to explain how heparin contributes to reduce the
levels of edema produced by B. erythromelas venom. lt is known that
heparin is constituted of radical sulfates, which make it possible to interact
electrostaticaly with diverse proteic locations of a basic character,
including phospholipase A2 which is present in the Bothrops atrox, B.
erythromelas and in diverse venom of other kinds and species of snakes21.
Heparin was capable of neutralizing the phospholipasic activity of the
Bothrops atrox and Bothrops erythromelas venom on an average of 14.3%
and 28.0% respectively (Table 5). Given that fact, the Bothrops
erythromelas venom produces less local tissue destruction allowing
heparin access to the inoculation site where, by electrostatic interaction,
it would reduce the phospholipasic activity of Bothrops erythromelas
venom, with a consequent reduction of edema.
Study of Neutralizing Effect of Heparin on Lethality: Heparin (dose
3 IU), prolonged Time of Death of the animals which received the
Bothrops atrox and Bothrops erythromelas venom, but did not keep the
animals alive (Table 6). The animals that received the venom with heparin
presented macroscopic lesions of greater intensity. lt is interesting to
point out that there was a difference in the macroscopic lesions provoked
by the venom; those that received the Bothrops atrox venom died with
rhinorrhagia, not present in the control animals and in those which
received the Bothrops erythromelas venom.
Necropsy revealed that envenomed mice treated with heparin
presented, when compared with control animals: (a) more intense
intracranial hemorrhaging; (b) macroscopic signs of intense pulmonary
hemorrhaging; (c) a higher increase in the weights of lungs and brain.
However, the increase was not statistically significant. On the other hand,
the hystological sections of the animals injected with Bothrops atrox
venom confirmed the intensity of lesions observed macroscopically, as
well as confirmed that heparin potentialized the hemorrhagic activity,
even in small doses (3IU) (personal communication of Dr. Luiz Carlos
de Lima Ferreira – Laboratório de Patologia, Instituto de Medicina
Tropical do Amazonas, Manaus, Amazonas, Brazil).
Many authors reported intracranial hemorrhaging produced by
ophidian accidents4,14,31. KOUYOUMDJIAN20, showed six cases of
patients with serious bothropic poisoning experiencing intracranial
hemorrhaging, where four led to death, one survived with sequel and
one without it. This indicates that the poisoning produced in Time of
Death experiment was serious. Comparing the groups by intensity of
the hemorrhagic phenomena, it suggests that heparin can increase the
gravity of the accidents.
The antibothropic serum was more effective in neutralizing the
lethality of the Bothrops atrox venom (100% protection), but promoted
Table 5
Neutralization of the phospholipase A2 activity of the venom Bothrops atrox and Bothrops erythromelas
Bothrops atrox Bothrops erythromelas Heparin (IU) Antibothropic Hemolysis halo (mm2) Neutralization (%)
+ - - - 2.1 -
+ - + - 1.8 14.3
+ - - + 1.6 23.8
- + - - 2.5 -
- + + - 1.8 28.0
- + - - 2.1 16.0
Table 6
Effect of the Heparin (3 IU) on time of death
Time of Death (min)
Groups Bothrops atrox Bothrops erythromelas
Control (Venom) 9.0 ± 2.6 5.3±0.3
Heparin 3 UI 26.7 ± 18.4 11.2±1.9
Antibothropic - *
Antibothropic + Heparin 3UI - **
(-) did not die; (*) protection of 58%; (**) protection of 92%
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only 58% protection against the lethality of the Bothrops erythromelas
venom. Heparin increased the efficacy of the bothropic antivenom for
Bothrops erythromelas when associated with this antivenom (92%
protection). A possible explanation could be that heparin interacted with
diverse fractions of the venom making the efficacy of the antibothropic
better, considering that heparin does not interfere with the ability of the
antibothropic in neutralizing the hemorrhagic activity of Bothrops
erythromelas venom (Table 4).
The differences observed in the neutralization of the activities of
both venom calls into question the efficacy of the antibothropic serum
supplied by the Ministry of Health. The Antibothropic Serum (ABS)
was less effective in neutralizing the lethal activity of Bothrops
erythromeIas venom. This snake is responsible for most of the ophidian
accidents in Northeast of Brazil and its venom is not included in the
production of this immunobiologic.
RESUMO
Associação de heparina e antiveneno: eficácia da neutralização
dos venenos de Bothrops atrox e Bothrops erythromelas
A heparina tem sido utilizada no tratamento dos acidentes botrópicos
em algumas regiões do Brasil, porém, os dados encontrados na literatura
são inconclusivos sobre sua eficácia. Os venenos de Bothrops atrox e de
B. erythromelas foram caracterizados segundo suas atividades biológicas.
A capacidade da heparina em neutralizar estas atividades foi testada com
as doses de 3 e 6UI de forma isolada e associada ao soro Antibotrópico
(SAB). Verificou-se que a heparina nas doses de 3 e 6UI, não foi eficaz
em neutralizar a atividade desfibrinante e edematogênica do veneno de
B. atrox e as ações hemorrágica e coagulante dos dois venenos. A heparina
diminuiu a eficácia do soro SAB na neutralização das atividades
hemorrágica e edematogênica do veneno de B. atrox. Contudo, a heparina
na dose de 6UI foi capaz de neutralizar a atividade edematogênica do
veneno de B. erythromelas e aumentar a eficácia do soro SAB. A heparina
neutralizou ainda a atividade fosfolipásica A2 dos venenos de B. atrox
(14,3%) e de B. erythromelas (28,0%). Para o veneno de B. erythromelas,
o tratamento associado de heparina e soro SAB, foi mais eficaz na
neutralização da atividade letal.
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